Recon: FDA places Legend Biotech’s early-stage CAR-T on hold; Lilly reunites with Immunogen with ADC deal

• Pfizer Sues Teva, Slayback to Block Copies of Two Xeljanz Doses (Bloomberg)
• Legend’s early-stage CAR-T on FDA hold after single patient dosed (Fierce) (Endpoints)
• Larimar kept in limbo as FDA maintains clinical hold on leading candidate (Fierce)
• J&J Starts Trial on Bankruptcy Case Under Attack by Congress (Bloomberg)
• Lilly reunites with Immunogen to expand into ADCs, paying $13M upfront and $1.7B on the back end (Fierce)
• FTC To Study Impact Of PBM Practices On Drug Prices, Pharmacies (Inside Health Policy)
• With $1.7T in the coffers, biopharma M&A expected to be ‘a different animal’ in 2022 (Fierce)

• EU Reveals Plans For Unitary SPC & Review Of Compulsory Licensing (The Pink Sheet)
• EMA follows FDA in scrutinizing safety of certain immune drugs (BioPharma Dive)
• Lynparza On Track For Broad Frontline Use In Prostate Cancer (Scrip)
• Israel to offer AstraZeneca's Evusheld to immunocompromised people (Reuters)
• No more waffling: Belgium discloses penalties for failing to report clinical trial results (STAT)
• Biden’s Global Vaccine Push Falters, Echoing U.S. Struggles (Bloomberg)
• Canadian HTA Announces New Program To Generate Real World Evidence (The Pink Sheet)

• Omicron threat remains high in east Europe – WHO (Reuters)
• China's potential mRNA COVID vaccine weaker against Omicron-study (Reuters)
• Vaccine scientists have been chasing variants. Now, they’re seeking a universal coronavirus vaccine. (Washington Post)

• Small pain drug player gets snapped up in $604M buyout — and the axe will soon fall (Endpoints)
• Novartis is chopping 400 jobs in India after striking new distribution pact (Endpoints)
• The top 10 M&A targets in biotech for 2022 (Fierce)
• Cipla Founding Family Pares Stake But Third Generation Affirms Continuity (Scrip)
• Pharma companies rarely default on debt, but it remains a risk factor for investors (STAT)
• AC Immune’s Janssen-partnered Alzheimer’s vaccine spurs tau-attacking antibodies in early-stage trial (Fierce)
• Amgen sees potential for KRAS drug in treating pancreatic cancer (BioPharma Dive)
• Pharma Supply Chain Disruptions Increased Another 74% in 2021, Resilinc Says (The Pink Sheet)
• Intellia-ONK ink up to $920M pact for 5 CRISPR-edited cancer cell therapies (Fierce)
• Kallyope, with ex-Merck exec at helm, skirts ‘less desirable’ public markets with $236M series D (Fierce)
• Cytokinetics' latest PhIII study of omecamtiv flops — kicking out another leg from under the market case it was building (Endpoints)
• AI startup grabs $60M, unveils platform aimed at drug discovery's 'data problem' (Endpoints)
• NMD pulls in $40M from Jeito-led, Roche-backed syndicate. Gaining financial muscle to crack myasthenia gravis market (Fierce) (Endpoints)

• Latest Essure data show more patients had device removed (MedTech Dive)
• Inflationary risk 'manageable' for medtechs but impact will vary: RBC (MedTech Dive)
• Senseonics Projects Slow Growth In 2022 Despite FDA Approval Of Eversense E3 CGM (MedTech Insight)

• GSK joins a crowd of pharma companies restricting sales under federal program (Endpoints)
• Endo Opioid Saga 'Like A John Grisham Movie,' Judge Says (Law360)
• Henrietta Lacks’ Heir Fights Firm’s Bid to End Compensation Case (Bloomberg)